Oppenheimer analyst Jeff Jones reiterated an Outperform rating and $23.00 price target on Y-mAbs Therapeutics (NASDAQ: YMAB).The analyst commented: "On ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE